Maintaining consistent levodopa benefits while simultaneously controlling dyskinesia can be difficult. Recently, an amantadine delayed release/extended release (DR/ER) formulation (Gocovri) indicated for dyskinesia received additional FDA approval as an adjunct to levodopa for the treatment of OFF episodes. We evaluated OFF time reductions with amantadine-DR/ER in a pooled analysis of two phase III amantadine-DR/ER trials (NCT02136914, NCT02274766) followed by a 2-year open-label extension trial (NCT02202551). OFF outcomes were analyzed for the mITT population, as well as stratified by baseline OFF time of ≥2.5 h/day or <2.5 h/day. At Week 12, mean placebo-subtracted treatment difference in OFF time was -1.00 [-1.57, -0.44] h in the mITT population (n = 196), -1.2 [-2.08, -0.32] h in the ≥2.5 h subgroup (n = 102) and -0.77 [-1.49, -0.06] in the <2.5 h subgroup (n = 94). Amantadine-DR/ER-treated participants showed reduced MDS-UPDRS Part IV motor fluctuation subscores by week 2 that were maintained below baseline to Week 100.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933492 | PMC |
| http://dx.doi.org/10.1038/s41531-022-00291-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Delayed drug-induced catatonia in an adolescent girl-clinical implications: a case report.
J Med Case Rep
November 2024
Division of Child and adolescent psychiatry, Uppsala Academic Hospital, Uppsala, Sweden.
Article Synopsis
- Catatonia is a serious condition marked by psychiatric and motor issues, often linked with various mental illnesses, and may have a high mortality rate; its exact cause and classification remain debated among experts.
- A rare case involved a 17-year-old girl who developed catatonia after recreational drug use, with symptoms appearing a week later, and she had no prior mental health issues or substance abuse history.
- Treatment with lorazepam, memantine, and lithium successfully improved her condition, emphasizing the need for early recognition of psychomotor symptoms and suggesting that certain drugs may cause delayed onset catatonia, particularly in adolescents.
Baseline-dependent enhancement of working memory by memantine in male rats: Involvement of NMDA receptor subunits and CaMKII signaling.
Pharmacol Biochem Behav
December 2024
Department of Psychology, Asia University, Taichung, Taiwan; Institute of Neuroscience, National Cheng-Chi University, Taipei, Taiwan; Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, Taiwan. Electronic address:
Article Synopsis
- NMDA receptors, which are activated by glutamate, are essential for learning and memory, and memantine (MEM) is used to manage symptoms in Alzheimer’s but may also have cognitive benefits in healthy individuals.
- A study on male rats tested MEM's effects on working memory through a T-maze task, finding that MEM improved performance, especially in those with initially poorer memory skills.
- Neurochemical analysis revealed that certain protein expressions in brain regions were linked to task performance, indicating that the benefits of MEM could depend on an individual’s baseline working memory capability.
Spectrum of delayed post-hypoxic leukoencephalopathy syndrome: A systematic review.
World J Clin Cases
October 2024
Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01655, United States.
Article Synopsis
- Delayed post hypoxic leukoencephalopathy syndrome (DPHLS) is a rare neurological condition that emerges weeks after hypoxia, causing cognitive and neurological deficits that are challenging to diagnose and treat.
- The study aims to gather and synthesize existing knowledge on DPHLS, focusing on its biological mechanisms, symptoms, diagnostic methods, and management while identifying areas needing more research.
- A review of 73 cases indicated that hypoxia often results from substance overdoses (like benzodiazepines and opioids), with common symptoms including cognitive decline and abnormal neuroimaging findings showing changes in the brain's white matter.
Recent Advances in Medicinal Chemistry of Memantine Against Alzheimer's Disease.
Chem Biol Drug Des
October 2024
Himachal Pradesh Technical University, Hamirpur, India.
Alzheimer's disease (AD) is a chronic progressive, age-related neurodegenerative brain disorder characterized by the irreversible decline of memory and other cognitive functions. It is one of the major health threat of the 21st century, which affects around 60% of the population over the age of 60 years. The problem of this disease is even more major because the existing pharmacotherapies only provide symptomatic relief without addressing the basic factors of the disease.
View Article and Find Full Text PDFDrugs with glutamate-based mechanisms of action in psychiatry.
Pharmacol Rep
December 2024
Department of Affective Disorders, Jagiellonian University Medical College, Kopernika 21A, 31-501, Kraków, Poland.
Psychopharmacotherapy of major psychiatric disorders is mostly based on drugs that modulate serotonergic, dopaminergic, or noradrenergic neurotransmission, either by inhibiting their reuptake or by acting as agonists or antagonists on specific monoamine receptors. The effectiveness of this approach is limited by a significant delay in the therapeutic mechanism and self-perpetuating growth of treatment resistance with a consecutive number of ineffective trials. A growing number of studies suggest that drugs targeting glutamate receptors offer an opportunity for rapid therapeutic effect that may overcome the limitations of monoaminergic drugs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!